Time-varying brentuximab vedotin pharmacokinetics and weight-based dosing in paediatric patients despite lower exposure in those aged 2 to <6 and 6-11 years.
Daping ZhangZufei ZhangAnthony LeeKeenan FentonShweta JainAmit GargYen Lin ChiaPublished in: British journal of clinical pharmacology (2024)
BV pharmacokinetics in adult and paediatric patients were consistent. BV ADC exposures were lower in patients aged 2 to <12 years vs. ≥12 years, but no apparent clinically relevant differences in efficacy, grade ≥2 PN or grade ≥3 neutropenia were observed. These data support body weight-based dosing of BV in patients irrespective of age; thus, dose adjustment in those 2 to <12 years does not appear warranted.
Keyphrases
- end stage renal disease
- newly diagnosed
- ejection fraction
- prognostic factors
- body weight
- emergency department
- peritoneal dialysis
- intensive care unit
- magnetic resonance imaging
- machine learning
- physical activity
- air pollution
- patient reported outcomes
- weight loss
- inflammatory response
- lps induced
- artificial intelligence
- patient reported